Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


19.11.2018

1 AJR Am J Roentgenol
1 Am J Clin Oncol
1 Ann Thorac Surg
1 BMC Cancer
1 Br J Cancer
1 Cancer Lett
1 Carcinogenesis
1 Chest
2 Clin Cancer Res
1 Clin Lung Cancer
2 Int J Cancer
3 Int J Oncol
1 J Cancer Res Clin Oncol
1 J Natl Cancer Inst
1 J Thorac Cardiovasc Surg
1 JAMA Oncol
29 Lung Cancer
2 N Engl J Med
6 Oncol Rep
2 Thorax


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJR Am J Roentgenol

  1. OHNO Y, Yui M, Chen Y, Kishida Y, et al
    Gadolinium-Based Blood Volume Mapping From MRI With Ultrashort TE Versus CT and SPECT for Predicting Postoperative Lung Function in Patients With Non-Small Cell Lung Cancer.
    AJR Am J Roentgenol. 2018 Nov 13:1-10. doi: 10.2214/AJR.18.20095.
    PubMed     Text format     Abstract available


    Am J Clin Oncol

  2. RATHOD S, Koul R, Bashir B, Chowdhury A, et al
    Role of Stereotactic Body Radiation Therapy in Early Stage Small Cell Lung Cancer in the Era of Lung Cancer Screening: A Systematic Review.
    Am J Clin Oncol. 2018 Nov 8. doi: 10.1097/COC.0000000000000489.
    PubMed     Text format     Abstract available


    Ann Thorac Surg

  3. CHUNG JM, Simmerman E, Sadek R, Wojtowicz S, et al
    Financial analysis of free lung cancer screening program shows profitability using broader NCCN Guidelines.
    Ann Thorac Surg. 2018 Nov 9. pii: S0003-4975(18)31624.
    PubMed     Text format     Abstract available


    BMC Cancer

  4. SEIGNEURIN A, Delafosse P, Tretarre B, Woronoff AS, et al
    Are comorbidities associated with long-term survival of lung cancer? A population-based cohort study from French cancer registries.
    BMC Cancer. 2018;18:1091.
    PubMed     Text format     Abstract available


    Br J Cancer

  5. TSE LA, Lin X, Li W, Qiu H, et al
    Smoking cessation sharply reduced lung cancer mortality in a historical cohort of 3185 Chinese silicotic workers from 1981 to 2014.
    Br J Cancer. 2018 Nov 13. pii: 10.1038/s41416-018-0292.
    PubMed     Text format     Abstract available


    Cancer Lett

  6. HUANG WT, Chong IW, Chen HL, Li CY, et al
    Pigment epithelium-derived factor inhibits lung cancer migration and invasion by upregulating exosomal thrombospondin 1.
    Cancer Lett. 2018 Nov 12. pii: S0304-3835(18)30646.
    PubMed     Text format     Abstract available


    Carcinogenesis

  7. ZHANG Y, Roth JA, Yu H, Ye Y, et al
    A 5-MicroRNA Signature Identified from Serum MicroRNA Profiling Predicts Survival in Patients with Advanced Stage Non-Small Cell Lung Cancer.
    Carcinogenesis. 2018 Nov 14. pii: 5183282. doi: 10.1093.
    PubMed     Text format     Abstract available


    Chest

  8. KALE MS, Wisnivesky J, Taioli E, Liu B, et al
    The Landscape of United States Lung Cancer Screening Services.
    Chest. 2018 Nov 9. pii: S0012-3692(18)32720-X. doi: 10.1016/j.chest.2018.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  9. LI L, Li W, Chen N, Zhao H, et al
    FLI1 exonic circular RNAs as a novel oncogenic driver to promote tumor metastasis in small cell lung cancer.
    Clin Cancer Res. 2018 Nov 14. pii: 1078-0432.CCR-18-1447.
    PubMed     Text format     Abstract available

  10. ESAI SELVAN M, Klein RJ, Gumus ZH
    Rare, pathogenic germline variants in Fanconi Anemia genes increase risk for squamous lung cancer.
    Clin Cancer Res. 2018 Nov 13. pii: 1078-0432.CCR-18-2660.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  11. CHAE YK, Davis AA, Raparia K, Agte S, et al
    Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2018 Sep 25. pii: S1525-7304(18)30253.
    PubMed     Text format     Abstract available


    Int J Cancer

  12. FORTUNATO O, Borzi C, Milione M, Centonze G, et al
    Circulating mir-320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31988.
    PubMed     Text format     Abstract available

  13. ZHAO S, Zhang Z, Zhang Y, Hong S, et al
    Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
    Int J Cancer. 2018 Nov 14. doi: 10.1002/ijc.31995.
    PubMed     Text format     Abstract available


    Int J Oncol

  14. ZHAO H, Chen G, Ye L, Yu H, et al
    DOK7V1 influences the malignant phenotype of lung cancer cells through PI3K/AKT/mTOR and FAK/paxillin signaling pathways.
    Int J Oncol. 2018 Nov 5. doi: 10.3892/ijo.2018.4624.
    PubMed     Text format     Abstract available

  15. CHEN L, Zhou Y, Tang X, Yang C, et al
    EGFR mutation decreases FDG uptake in nonsmall cell lung cancer via the NOX4/ROS/GLUT1 axis.
    Int J Oncol. 2018 Nov 6. doi: 10.3892/ijo.2018.4626.
    PubMed     Text format     Abstract available

  16. XU YH, Tu JR, Zhao TT, Xie SG, et al
    Overexpression of lncRNA EGFRAS1 is associated with a poor prognosis and promotes chemotherapy resistance in nonsmall cell lung cancer.
    Int J Oncol. 2018 Nov 9. doi: 10.3892/ijo.2018.4629.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  17. GUO T, Li J, Zhang L, Hou W, et al
    Multidimensional communication of microRNAs and long non-coding RNAs in lung cancer.
    J Cancer Res Clin Oncol. 2018 Nov 11. pii: 10.1007/s00432-018-2767.
    PubMed     Text format     Abstract available


    J Natl Cancer Inst

  18. YANG R, Li SW, Chen Z, Zhou X, et al
    Role of INSL4 Signaling in Sustaining the Growth and Viability of LKB1-Inactivated Lung Cancer.
    J Natl Cancer Inst. 2018 Nov 13. pii: 5181309. doi: 10.1093.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  19. BRANDT WS, Yan W, Zhou J, Tan KS, et al
    Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: A propensity-matched analysis.
    J Thorac Cardiovasc Surg. 2018 Oct 10. pii: S0022-5223(18)32606.
    PubMed     Text format     Abstract available


    JAMA Oncol

  20. EZE C, Kasmann L, Manapov F
    Redefining the Role of Prophylactic Cranial Irradiation in the Modern Era of Active Surveillance in Small Cell Lung Cancer.
    JAMA Oncol. 2018 Oct 25. pii: 2707226. doi: 10.1001/jamaoncol.2018.4833.
    PubMed     Text format    


    Lung Cancer

  21. DJUREINOVIC D, Dodig-Crnkovic T, Hellstrom C, Holgersson G, et al
    Detection of autoantibodies against cancer-testis antigens in non-small cell lung cancer.
    Lung Cancer. 2018;125:157-163.
    PubMed     Text format     Abstract available

  22. FROST N, Tessmer A, Schmittel A, van Laak V, et al
    Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients.
    Lung Cancer. 2018;125:164-173.
    PubMed     Text format     Abstract available

  23. KARLSSON T, Kvarnbrink S, Holmlund C, Botling J, et al
    LMO7 and LIMCH1 interact with LRIG proteins in lung cancer, with prognostic implications for early-stage disease.
    Lung Cancer. 2018;125:174-184.
    PubMed     Text format     Abstract available

  24. YUTAKA Y, Sonobe M, Kawaguchi A, Hamaji M, et al
    Prognostic impact of preoperative comorbidities in geriatric patients with early-stage lung cancer: Significance of sublobar resection as a compromise procedure.
    Lung Cancer. 2018;125:192-197.
    PubMed     Text format     Abstract available

  25. CHO JY, Kim J, Lee JS, Kim YJ, et al
    Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
    Lung Cancer. 2018;125:150-156.
    PubMed     Text format     Abstract available

  26. KAWANO Y, Sasaki T, Yamaguchi H, Hirano K, et al
    Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
    Lung Cancer. 2018;125:136-141.
    PubMed     Text format     Abstract available

  27. DEJIMA H, Nakanishi H, Kuroda H, Yoshimura M, et al
    Detection of abundant megakaryocytes in pulmonary artery blood in lung cancer patients using a microfluidic platform.
    Lung Cancer. 2018;125:128-135.
    PubMed     Text format     Abstract available

  28. MOFFAT J, Hiom S, Kumar HS, Baldwin DR, et al
    Lung cancer screening - gaining consensus on next steps - proceedings of a closed workshop in the UK.
    Lung Cancer. 2018;125:121-127.
    PubMed     Text format     Abstract available

  29. REN S, Tian Q, Amar N, Yu H, et al
    The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression.
    Lung Cancer. 2018;125:115-120.
    PubMed     Text format     Abstract available

  30. WALTER JE, Heuvelmans MA, de Bock GH, Yousaf-Khan U, et al
    Relationship between the number of new nodules and lung cancer probability in incidence screening rounds of CT lung cancer screening: The NELSON study.
    Lung Cancer. 2018;125:103-108.
    PubMed     Text format     Abstract available

  31. EZEIFE DA, Kirk V, Chew DS, Nixon NA, et al
    Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada.
    Lung Cancer. 2018;125:1-7.
    PubMed     Text format     Abstract available

  32. MALHOTRA J, Rotter D, Jabbour SK, Aisner J, et al
    Receipt of recommended surveillance with imaging in elderly survivors of early stage non-small cell lung cancer.
    Lung Cancer. 2018;125:205-211.
    PubMed     Text format     Abstract available

  33. YAMAGUCHI T, Shimizu J, Hasegawa T, Horio Y, et al
    Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.
    Lung Cancer. 2018;125:212-217.
    PubMed     Text format     Abstract available

  34. COSTA GJ, de Mello MJG, Ferreira CG, Bergmann A, et al
    Increased incidence, morbidity and mortality rates for lung cancer in women in Brazil between 2000 and 2014: An analysis of three types of sources of secondary data.
    Lung Cancer. 2018;125:77-85.
    PubMed     Text format     Abstract available

  35. CHEN K, Yu X, Zhang F, Xu Y, et al
    Applicability of the lung-molGPA index in non-small cell lung cancer patients with different gene alterations and brain metastases.
    Lung Cancer. 2018;125:8-13.
    PubMed     Text format     Abstract available

  36. LIU SY, Dong ZY, Wu SP, Xie Z, et al
    Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
    Lung Cancer. 2018;125:86-92.
    PubMed     Text format     Abstract available

  37. HANIBUCHI M, Kakiuchi S, Atagi S, Ogushi F, et al
    A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.
    Lung Cancer. 2018;125:93-99.
    PubMed     Text format     Abstract available

  38. LUO Q, Yu XQ, Wade S, Caruana M, et al
    Lung cancer mortality in Australia: Projected outcomes to 2040.
    Lung Cancer. 2018;125:68-76.
    PubMed     Text format     Abstract available

  39. CHECK DK, Albers KB, Uppal KM, Suga JM, et al
    Examining the role of access to care: Racial/ethnic differences in receipt of resection for early-stage non-small cell lung cancer among integrated system members and non-members.
    Lung Cancer. 2018;125:51-56.
    PubMed     Text format     Abstract available

  40. SOTIROPOULOS GP, Dalamaga M, Antonakos G, Marinou I, et al
    Chemerin as a biomarker at the intersection of inflammation, chemotaxis, coagulation, fibrinolysis and metabolism in resectable non-small cell lung cancer.
    Lung Cancer. 2018;125:291-299.
    PubMed     Text format     Abstract available

  41. BALATA H, Foden P, Edwards T, Chaturvedi A, et al
    Predicting survival following surgical resection of lung cancer using clinical and pathological variables: The development and validation of the LNC-PATH score.
    Lung Cancer. 2018;125:29-34.
    PubMed     Text format     Abstract available

  42. LIN MW, Su KY, Su TJ, Chang CC, et al
    Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lung Cancer. 2018;125:282-290.
    PubMed     Text format     Abstract available

  43. GADGEEL SM, Stevenson JP, Langer CJ, Gandhi L, et al
    Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
    Lung Cancer. 2018;125:273-281.
    PubMed     Text format     Abstract available

  44. ISOBE K, Kaburaki K, Kobayashi H, Sano G, et al
    New risk scoring system for predicting acute exacerbation of interstitial pneumonia after chemotherapy for lung cancer associated with interstitial pneumonia.
    Lung Cancer. 2018;125:253-257.
    PubMed     Text format     Abstract available

  45. WANG S, Zhang B, Qian J, Qiao R, et al
    Proposal on incorporating lymphovascular invasion as a T-descriptor for stage I lung cancer.
    Lung Cancer. 2018;125:245-252.
    PubMed     Text format     Abstract available

  46. JEGOU D, Dubois C, Schillemans V, Stordeur S, et al
    Use of health insurance data to identify and quantify the prevalence of main comorbidities in lung cancer patients.
    Lung Cancer. 2018;125:238-244.
    PubMed     Text format     Abstract available

  47. SAITO T, Tsuta K, Ishida M, Ryota H, et al
    Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients.
    Lung Cancer. 2018;125:230-237.
    PubMed     Text format     Abstract available

  48. KORT S, Tiggeloven MM, Brusse-Keizer M, Gerritsen JW, et al
    Multi-centre prospective study on diagnosing subtypes of lung cancer by exhaled-breath analysis.
    Lung Cancer. 2018;125:223-229.
    PubMed     Text format     Abstract available

  49. JIA Y, Li X, Zhao C, Jiang T, et al
    Impact of serum vascular endothelial growth factor and interleukin-6 on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
    Lung Cancer. 2018;125:22-28.
    PubMed     Text format     Abstract available


    N Engl J Med

  50. PATIL T, Pacheco JM
    Miliary Metastases in Non-Small-Cell Lung Cancer.
    N Engl J Med. 2018;379:1945.
    PubMed     Text format    

  51. NEILAN TG, Price MC, Sanborn DY, Gainor JF, et al
    Case 33-2018: A 57-Year-Old Man with Confusion, Fever, Malaise, and Weight Loss.
    N Engl J Med. 2018;379:1658-1669.
    PubMed     Text format    


    Oncol Rep

  52. LOU Z, Lee BS, Ha T, Xu Y, et al
    ESE1 suppresses the growth, invasion and migration of human NSCLC cells and tumor formation in vivo.
    Oncol Rep. 2018;40:1734-1742.
    PubMed     Text format     Abstract available

  53. ZHANG G, Fang T, Chang M, Li J, et al
    Calpain 2 knockdown promotes cell apoptosis and restores gefitinib sensitivity through epidermal growth factor receptor/protein kinase B/survivin signaling.
    Oncol Rep. 2018;40:1937-1946.
    PubMed     Text format     Abstract available

  54. MOHAMMED A, Zhang C, Zhang S, Shen Q, et al
    Inhibition of cell proliferation and migration in nonsmall cell lung cancer cells through the suppression of LYPLA1.
    Oncol Rep. 2018 Nov 9. doi: 10.3892/or.2018.6857.
    PubMed     Text format     Abstract available

  55. LAI YH, Liu HY, Huang CY, Chau YP, et al
    MitochondrialDNAassociated TLR9 signalling is a potential serological biomarker for nonsmall cell lung cancer.
    Oncol Rep. 2018 Nov 9. doi: 10.3892/or.2018.6855.
    PubMed     Text format     Abstract available

  56. XU H, Jiao X, Wu Y, Li S, et al
    Exosomes derived from PM2.5treated lung cancer cells promote the growth of lung cancer via the Wnt3a/betacatenin pathway.
    Oncol Rep. 2018 Nov 9. doi: 10.3892/or.2018.6862.
    PubMed     Text format     Abstract available

  57. ONODERA K, Sakurada A, Notsuda H, Watanabe T, et al
    Growth inhibition of KRAS and EGFRmutant lung adenocarcinoma by cosuppression of STAT3 and the SRC/ARHGAP35 axis.
    Oncol Rep. 2018;40:1761-1768.
    PubMed     Text format     Abstract available


    Thorax

  58. CROSBIE PA, Balata H, Evison M, Atack M, et al
    Second round results from the Manchester 'Lung Health Check' community-based targeted lung cancer screening pilot.
    Thorax. 2018 Nov 12. pii: thoraxjnl-2018-212547.
    PubMed     Text format     Abstract available

  59. XU KF, Tian X, Yang Y, Zhang H, et al
    Rapamycin for lymphangioleiomyomatosis: optimal timing and optimal dosage.
    Thorax. 2018;73:308-310.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: